Trexquant Investment LP Buys 25,260 Shares of Cryoport, Inc. (NASDAQ:CYRX)

Trexquant Investment LP raised its position in Cryoport, Inc. (NASDAQ:CYRX) by 11.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 239,138 shares of the company’s stock after buying an additional 25,260 shares during the period. Trexquant Investment LP’s holdings in Cryoport were worth $1,860,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in CYRX. Geode Capital Management LLC lifted its stake in shares of Cryoport by 3.6% during the third quarter. Geode Capital Management LLC now owns 1,097,369 shares of the company’s stock valued at $8,902,000 after acquiring an additional 38,520 shares during the period. State Street Corp boosted its stake in shares of Cryoport by 2.8% in the 3rd quarter. State Street Corp now owns 1,003,080 shares of the company’s stock valued at $8,135,000 after purchasing an additional 27,438 shares during the last quarter. LPL Financial LLC grew its position in shares of Cryoport by 1,366.1% during the 4th quarter. LPL Financial LLC now owns 436,766 shares of the company’s stock worth $3,398,000 after buying an additional 406,976 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Cryoport by 0.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 387,714 shares of the company’s stock worth $3,144,000 after buying an additional 2,226 shares during the last quarter. Finally, Franklin Resources Inc. lifted its holdings in Cryoport by 0.4% in the fourth quarter. Franklin Resources Inc. now owns 387,131 shares of the company’s stock valued at $3,012,000 after buying an additional 1,512 shares during the period. 92.90% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have commented on CYRX. Roth Mkm reaffirmed a “buy” rating and set a $15.00 target price on shares of Cryoport in a report on Tuesday, April 1st. Guggenheim assumed coverage on Cryoport in a report on Thursday, December 19th. They issued a “buy” rating and a $11.00 price objective for the company. UBS Group raised their target price on Cryoport from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Tuesday, April 1st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price target on shares of Cryoport in a research note on Monday, March 31st. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $11.83.

Insider Buying and Selling at Cryoport

In other news, CEO Jerrell Shelton sold 4,620 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $6.29, for a total transaction of $29,059.80. Following the completion of the transaction, the chief executive officer now directly owns 765,399 shares of the company’s stock, valued at $4,814,359.71. This trade represents a 0.60 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 19,830 shares of company stock valued at $118,353 in the last 90 days. 10.10% of the stock is currently owned by company insiders.

Cryoport Stock Down 9.8 %

NASDAQ:CYRX opened at $4.95 on Wednesday. Cryoport, Inc. has a 1 year low of $4.58 and a 1 year high of $19.00. The stock has a 50-day moving average price of $6.28 and a two-hundred day moving average price of $7.16. The stock has a market cap of $247.05 million, a price-to-earnings ratio of -1.46 and a beta of 1.81. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48.

Cryoport (NASDAQ:CYRX) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.09). The company had revenue of $59.53 million for the quarter, compared to the consensus estimate of $58.71 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. During the same period in the prior year, the company earned ($0.29) EPS. As a group, equities analysts expect that Cryoport, Inc. will post -0.99 earnings per share for the current year.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.